Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

Abstract

Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior. The deuterium kinetic isotope effect (KIE), which strengthens carbon–deuterium bonds, make it possible to improve therapeutic efficacy while maintaining pharmacological activity. Although some deuterated drugs, notably donafenib and deutetrabenazine, have demonstrated clinically significant efficacy, their limited use is an effect of ongoing challenges with metabolic switching and species-specific variation, as well as inadequate mechanistic understanding. This review presents a systematic discussion of the recent innovations in site-selective deuteration, the principles that underpin the KIE process, and the effects of deuterium substitution on drug metabolism, toxicity, and blood–brain barrier penetration. It illustrates novel implications in oncology, rare diseases, and central nervous system disorders, as well as the integration of deuterated chemistry with modalities such as proteolysis-targeting chimaeras, peptides, and nucleic acid therapeutics. Furthermore, the review's discussion includes the current challenges, synthesis, analytical limits, and regulatory considerations that influence further development. Overall, the review offers a strategic roadmap for utilizing deuterium-enabled molecular engineering to accelerate the development of next-generation precision medicine, guiding rational design, innovation toward safer, longer-lasting, and more effective treatments.

Keywords

deucravacitinib / deuterated drugs / deuterium / drug metabolism / pharmacokinetic properties

References

[1] T. G. Gant, “Using Deuterium in Drug Discovery: Leaving the Label in the Drug,” Journal of Medicinal Chemistry 57, no. 9 (2014): 3595–3611.

[2] V. Kselíková, M. Vítová, and K. Bišová, “Deuterium and Its Impact on Living Organisms,” Folia Microbiologica (Praha) 64, no. 5 (2019): 673–681.

[3] K. Sanderson, “Big Interest in Heavy Drugs,” Nature 458, no. 7236 (2009): 269.

[4] R. Petroski, E. Bates, B. Dionne, et al., “Design of a Direct-cycle Supercritical CO2 Nuclear Reactor With Heavy Water Moderation,” Nuclear Engineering and Technology 54, no. 3 (2022): 877–887.

[5] D. O. Claassen, B. Carroll, L. M. De Boer, et al., “Indirect Tolerability Comparison of Deutetrabenazine and Tetrabenazine for Huntington Disease,” Journal of Clinical Movement Disorders 4, no. 1 (2017): 3.

[6] R. M. C. Di Martino, B. D. Maxwell, and T. Pirali, “Deuterium in Drug Discovery: Progress, Opportunities and Challenges,” Nature Reviews Drug Discovery 22, no. 7 (2023): 562–584.

[7] S. M. Hoy, “Deucravacitinib: First Approval,” Drugs 82, no. 17 (2022): 1671–1679.

[8] S. L. Harbeson and R. D. Tung, “Deuterium in Drug Discovery and Development,” in Annual Reports in Medicinal Chemistry, ed. J. E. Macor, (Academic Press, 2011), 403–417.

[9] A. J. Khan, S. M. Misenko, A. Thandoni, et al., “VX-984 Is a Selective Inhibitor of Non-homologous End Joining, With Possible Preferential Activity in Transformed Cells,” Oncotarget 9, no. 40 (2018): 25833–25841.

[10] C. Liu, J. Lin, C. Langevine, et al., “Discovery of BMS-986202: A Clinical Tyk2 Inhibitor That Binds to Tyk2 JH2,” Journal of Medicinal Chemistry 64, no. 1 (2021): 677–694.

[11] L. Hernychova, P. Man, C. Verma, et al., “Identification of a Second Nutlin-3 Responsive Interaction Site in the N-terminal Domain of MDM2 Using Hydrogen/Deuterium Exchange Mass Spectrometry,” Proteomics 13, no. 16 (2013): 2512–2525.

[12] L. Liu, P. D. Johnson, M. E. Prime, et al., “Design and Evaluation of [18F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates,” Journal of Medicinal Chemistry 66, no. 1 (2023): 641–656.

[13] T. Yang, X. Cui, M. Tang, et al., “Identification of a Novel 2,8-Diazaspiro[4.5]Decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease,” Journal of Medicinal Chemistry 65, no. 4 (2022): 3151–3172.

[14] P. Purushottamachar, E. Thomas, R. S. Thankan, and V. C. O. Njar, “Novel Deuterated Mnk1/2 Protein Degrader VNLG-152R Analogs: Synthesis, In Vitro Anti-TNBC Activities and Pharmacokinetics in Mice,” European Journal of Medicinal Chemistry 238 (2022): 114441.

[15] P. A. Fields, “Review: Protein Function at Thermal Extremes: Balancing Stability and Flexibility,” Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology 129, no. 2-3 (2001): 417–431.

[16] M. Yassari, A. Bagherzadeh, A. Docoslis, M. R. Daymond, and M. Sadrzadeh, “Advancements in Adsorption and Membrane Technologies for Hydrogen Isotope Separation: Exploring New Materials and Emerging Techniques,” Separation and Purification Technology 374 (2025): 133666.

[17] “Hydrogen,” in Chemistry of the Elements (Elsevier, 1997), 32–67.

[18] I. M. Svishchev and P. G. Kusalik, “Dynamics in Liquid Water, Water-d2, and Water-t2: A Comparative Simulation Study,” Journal of Physical Chemistry 98, no. 3 (1994): 728–733.

[19] J. Liu and X. Liu, “Deuterium,” in Deuteride Materials (Springer, 2019), 1–46.

[20] N. Penner, L. Xu, and C. Prakash, “Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: Why, When, and How?,” Chemical Research in Toxicology 25, no. 3 (2012): 513–531.

[21] T. Zhang, X. Deng, H. Jin, et al., “The Effect of Deuterated PLK1 Inhibitor on Its Safety and Efficacy in Vivo,” Frontiers in Oncology 15 (2025): 1510052.

[22] J. Atzrodt, V. Derdau, W. J. Kerr, and M. Reid, “Deuterium- and Tritium-Labelled Compounds: Applications in the Life Sciences,” Angewandte Chemie International Edition 57, no. 7 (2018): 1758–1784.

[23] G. S. Timmins, “Deuterated Drugs: Where Are We Now?,” Expert Opinion on Therapeutic Patents 24, no. 10 (2014): 1067–1075.

[24] J. F. Liu, S. L. Harbeson, C. L. Brummel, R. Tung, R. Silverman, and D. Doller, A Decade of Deuteration in Medicinal Chemistry (2017), 519–542.

[25] R. O. Saleh, M. T. S. Al-Ouqaili, E. Ali, et al., “lncRNA-microRNA Axis in Cancer Drug Resistance: Particular Focus on Signaling Pathways,” Medical Oncology 41, no. 2 (2024): 52.

[26] C. P. R. McCarter, F. Rezanezhad, B. Gharedaghloo, J. S. Price, and P. Van Cappellen, “Transport of Chloride and Deuterated Water in Peat: The Role of Anion Exclusion, Diffusion, and Anion Adsorption in a Dual Porosity Organic media,” Journal of Contaminant Hydrology 225 (2019): 103497.

[27] Y. Chen and Y. Du, “The Application of Deuteration Strategy in Drug Design,” Chemmedchem 20, no. 7 (2025): e202400836.

[28] R. P. Bell, “Liversidge Lecture. Recent Advances in the Study of Kinetic Hydrogen Isotope Effects,” Chemical Society Reviews 3, no. 4 (1974): 513.

[29] E. M. Russak and E. M. Bednarczyk, “Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals,” Annals of Pharmacotherapy 53, no. 2 (2019): 211–216.

[30] L. Li, J. Jakowski, C. Do, and K. Hong, “Deuteration and Polymers: Rich History With Great Potential,” Macromolecules 54, no. 8 (2021): 3555–3584.

[31] T. Pirali, M. Serafini, S. Cargnin, and A. A. Genazzani, “Applications of Deuterium in Medicinal Chemistry,” Journal of Medicinal Chemistry 62, no. 11 (2019): 5276–5297.

[32] K. Zangger, “Pure Shift NMR,” Progress in Nuclear Magnetic Resonance Spectroscopy 86-87 (2015): 1–20.

[33] M. Lecomte, M. Lahboubi, P. Thilmany, A. El Bouzakhi, and G. Evano, “A General, Versatile and Divergent Synthesis of Selectively Deuterated Amines,” Chemical Science 12, no. 33 (2021): 11157–11165.

[34] T. M. Belete, “Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer,” Drug Design, Development and Therapy 16 (2022): 3465–3472.

[35] S. Kopf, F. Bourriquen, W. Li, H. Neumann, K. Junge, and M. Beller, “Recent Developments for the Deuterium and Tritium Labeling of Organic Molecules,” Chemical Reviews 122, no. 6 (2022): 6634–6718.

[36] B. Jiang, J. Liu, Y. Li, et al., “Synthesis and Crystallization Research of Voclosporin,” Organic Process Research & Development 28, no. 4 (2024): 1151–1158.

[37] A. Katsnelson, “Heavy Drugs Draw Heavy Interest From Pharma Backers,” Nature Medicine 19, no. 6 (2013): 656–656.

[38] L. J. Altman, P. Laungani, G. Gunnarsson, H. Wennerstrom, and S. Forsen, “Proton, Deuterium, and Tritium Nuclear Magnetic Resonance of Intramolecular Hydrogen Bonds. Isotope Effects and the Shape of the Potential Energy Function,” Journal of the American Chemical Society 100, no. 26 (1978): 8264–8266.

[39] Z. Zhan, X. Peng, Y. Sun, J. Ai, and W. Duan, “Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles,” Chemical Research in Toxicology 31, no. 11 (2018): 1213–1218.

[40] A. E. Mutlib, “Application of Stable Isotope-Labeled Compounds in Metabolism and in Metabolism-Mediated Toxicity Studies,” Chemical Research in Toxicology 21, no. 9 (2008): 1672–1689.

[41] A. Sib and V. Derdau, “Method Development and Syntheses Examples of Isotopically Labeled Compounds to Foster Operational Excellence in Pharma Industry,” Synlett 35, no. 19 (2024): 2155–2173.

[42] L. Zhang, S. Zhang, Y. Zhang, B. Liu, X. Li, and B. Han, “Navigating the Deuteration Landscape: Innovations, Challenges, and Clinical Potential of Deuterioindoles,” Chembiochem 26, no. 5 (2025): e202400837.

[43] J. Chen, Y. Y. Zhu, L. Huang, S. S. Zhang, and S. X. Gu, “Application of Deuterium in Research and Development of Drugs,” European Journal of Medicinal Chemistry 287 (2025): 117371.

[44] D. Zhang, K. Robinson, and I. Washington, “C20D3-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes in a Mouse Model,” Translational Vision Science & Technology 10, no. 14 (2021): 8.

[45] R. P. Garay and G. T. Grossberg, “AVP-786 for the Treatment of Agitation in Dementia of the Alzheimer's Type,” Expert Opinion on Investigational Drugs 26, no. 1 (2017): 121–132.

[46] M. C. Chen, C. C. Korth, M. D. Harnett, E. Elenko, and J. D. Lickliter, “A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases,” Clinical Pharmacology in Drug Development 11, no. 2 (2022): 220–234.

[47] S. A. Harrison, C. Thang, S. Bolze, et al., “Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in Patients With NASH: A Phase II Randomized Placebo-controlled Trial (DESTINY-1),” Journal of Hepatology 78, no. 5 (2023): 914–925.

[48] V. Jacques, S. Bolze, S. Hallakou-Bozec, et al., “Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity,” Hepatology Communications 5, no. 8 (2021): 1412–1425.

[49] L. Perrem and F. Ratjen, “A New Triple Combination Cystic Fibrosis Transmembrane Regulator Modulator,” The Lancet Respiratory Medicine 11, no. 6 (2023): 499–500.

[50] D. W. Ye, C. Gu, L. Hua, et al., “Deutenzalutamide, an Oral Deuterated Androgen Receptor Inhibitor, vs Placebo for Patients With mCRPC Who Have Experienced Treatment Failure With Abiraterone and Docetaxel: Results of the HC-1119-04 Phase 3 Trial,” Journal of Clinical Oncology 41, no. 16_suppl (2023): 5065–5065.

[51] D. R. Lynch, K. D. Mathews, S. Perlman, et al., “Double Blind Trial of a Deuterated Form of Linoleic Acid (RT001) in Friedreich Ataxia,” Journal of Neurology 270, no. 3 (2023): 1615–1623.

[52] S. Qin, F. Bi, S. Gu, et al., “Donafenib versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial,” Journal of Clinical Oncology 39, no. 27 (2021): 3002–3011.

[53] H. J. Qian, Y. Wang, M. Q. Zhang, et al., “Safety, Tolerability, and Pharmacokinetics of VV116, an Oral Nucleoside Analog Against SARS-CoV-2, in Chinese Healthy Subjects,” Acta Pharmacologica Sinica 43, no. 12 (2022): 3130–3138.

[54] M. M. Senna, B. King, N. A. Mesinkovska, A. Mostaghimi, C. Hamilton, and J. Cassella, “41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients With Moderate to Severe Alopecia Areata: Results From the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial,” Journal of the American Academy of Dermatology 89, no. 3 (2023): AB43.

[55] L. Sabounjian, P. Graham, L. Wu, et al., “A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease,” Clinical Pharmacology in Drug Development 5, no. 4 (2016): 314–325.

[56] M. Bond, B. Murphy, B. Doran, et al., “Results of a Phase 1 Study Assessing the Effect of CIN-102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers,” Clinical Pharmacology in Drug Development 15, no. 3 (2026): e70039.

[57] R. Rosenberg, T. Roth, M. B. Scharf, D. A. Lankford, and R. Farber, “Efficacy and Tolerability of Indiplon in Transient Insomnia,” Journal of Clinical Sleep Medicine 3, no. 4 (2007): 374–379.

[58] V. Uttamsingh, R. Gallegos, C. Cheng, et al., “Abstract 3357: CTP-221, a Deuterated S-enantiomer of Lenalidomide, Is Greatly Stabilized to Epimerization and Results in a More Desirable Pharmacokinetic Profile Than Racemic Lenalidomide,” Cancer Research 73, no. 8_Supplement (2013): 3357–3357.

[59] K. Kassahun, C. Fandozzi, D. R. J. Gauthier, and L. A. Shipley, “Cathepsin cysteine protease inhibitors,” Published online 2012:WO2012112363.

[60] F. Maltais, Y. C. Jung, M. Chen, et al., “In Vitro and In Vivo Isotope Effects With Hepatitis C Protease Inhibitors: Enhanced Plasma Exposure of Deuterated Telaprevir versus Telaprevir in Rats,” Journal of Medicinal Chemistry 52, no. 24 (2009): 7993–8001.

[61] N. M. Midde, B. J. Patters, P. Rao, T. J. Cory, and S. Kumar, “Investigational Protease Inhibitors as Antiretroviral Therapies,” Expert Opinion on Investigational Drugs 25, no. 10 (2016): 1189–1200.

[62] N. Rao, R. Kini, and P. Kad, “Deuterated Drugs,” Pharmaceutical Chemistry Journal 55, no. 12 (2022): 1372–1377.

[63] U. M. Zanger and M. Schwab, “Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation,” Pharmacology & Therapeutics 138, no. 1 (2013): 103–141.

[64] S. D. Nelson and W. F. Trager, “The Use of Deuterium Isotope Effects To Probe THE Active Site Properties, Mechanism of Cytochrome P450-Catalyzed Reactions, and Mechanisms of Metabolically Dependent Toxicity,” Drug Metabolism and Disposition 31, no. 12 (2003): 1481–1498.

[65] F. P. Guengerich, Kinetic Deuterium Isotope Effects in Cytochrome P450 Reactions (2017), 217–238.

[66] J. Shanu-Wilson, L. Evans, S. Wrigley, J. Steele, J. Atherton, and J. Boer, “Biotransformation: Impact and Application of Metabolism in Drug Discovery,” Acs Medicinal Chemistry Letters 11, no. 11 (2020): 2087–2107.

[67] G. T. Miwa and A. Y. H. Lu, “Kinetic Isotope Effects and ‘Metabolic Switching’ in Cytochrome P450-catalyzed Reactions,” BioEssays 7, no. 5 (1987): 215–219.

[68] M. Gupta, “Deuteration as a Tool for Optimization of Metabolic Stability and Toxicity of Drugs,” Global Journal of Pharmacy & Pharmaceutical Sciences 1, no. 4 (2017): 555566.

[69] A. Bechalany, N. El Tayar, P. Carrupt, et al., “Isotope Effects on the Lipophilicity of Deuterated Caffeines,” Helvetica Chimica Acta 72, no. 3 (1989): 472–476.

[70] E. Bardin, A. Pastor, M. Semeraro, et al., “Modulators of CFTR. Updates on Clinical Development and Future Directions,” European Journal of Medicinal Chemistry 213 (2021): 113195.

[71] G. Pons and E. Rey, “Stable Isotopes Labeling of Drugs in Pediatric Clinical Pharmacology,” Pediatrics 104, no. Supplement_3 (1999): 633–639.

[72] W. A. Coward, R. G. Whitehead, M. B. Sawyer, A. M. Prentice, and J. Evans, “New Method for Measuring Milk Intakes in Breast-Fed Babies,” The Lancet 314, no. 8132 (1979): 13–14.

[73] A. H. MacLennan, G. Millington, A. Grieve, J. E. A. McIntosh, R. F. Seamark, and L. W. Cox, “Neonatal Body Water Turnover: A Putative Index of Perinatal Morbidity,” American Journal of Obstetrics and Gynecology 139, no. 8 (1981): 948–952.

[74] R. H. Howland, “Deuterated Drugs,” Journal of Psychosocial Nursing and Mental Health Services 53, no. 9 (2015): 13–16.

[75] B. Belleau, J. Burba, M. Pindell, and J. Reiffenstein, “Effect of Deuterium Substitution in Sympathomimetic Amines on Adrenergic Responses,” Science (1979) 133, no. 3446 (1961): 102–104.

[76] R. Sharma, T. J. Strelevitz, H. Gao, et al., “Deuterium Isotope Effects on Drug Pharmacokinetics. I. System-Dependent Effects of Specific Deuteration With Aldehyde Oxidase Cleared Drugs,” Drug Metabolism and Disposition 40, no. 3 (2012): 625–634.

[77] N. Manevski, L. King, W. R. Pitt, F. Lecomte, and F. Toselli, “Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery,” Journal of Medicinal Chemistry 62, no. 24 (2019): 10955–10994.

[78] F. Schneider, L. Erisson, H. Beygi, et al., “Pharmacokinetics, Metabolism and Safety of Deuterated L-DOPA (SD-1077)/Carbidopa Compared to L-DOPA/Carbidopa Following Single Oral Dose Administration in Healthy Subjects,” British Journal of Clinical Pharmacology 84, no. 10 (2018): 2422–2432.

[79] T. Malmlöf, D. Rylander, R. G. Alken, et al., “Deuterium Substitutions in the L-DOPA Molecule Improve Its Anti-akinetic Potency Without Increasing Dyskinesias,” Experimental Neurology 225, no. 2 (2010): 408–415.

[80] T. Malmlöf, K. Feltmann, Å. Konradsson-Geuken, et al., “Deuterium-substituted L-DOPA Displays Increased Behavioral Potency and Dopamine Output in an Animal Model of Parkinson's disease: Comparison With the Effects Produced by L-DOPA and an MAO-B Inhibitor,” Journal of Neural Transmission 122, no. 2 (2015): 259–272.

[81] J. Schofield, V. Derdau, J. Atzrodt, et al., “Effect of Deuteration on Metabolism and Clearance of Nerispirdine (HP184) and AVE5638,” Bioorganic & Medicinal Chemistry 23, no. 13 (2015): 3831–3842.

[82] H. Sun, D. W. Piotrowski, S. T. M. Orr, et al., “Deuterium Isotope Effects in Drug Pharmacokinetics II: Substrate-dependence of the Reaction Mechanism Influences Outcome for Cytochrome P450 Cleared Drugs,” PLoS ONE 13, no. 11 (2018): e0206279.

[83] L. Shao and M. C. Hewitt, “The Kinetic Isotope Effect in the Search for Deuterated Drugs,” Drug News & Perspectives 23, no. 6 (2010): 398.

[84] V. V. Demidov, “Site-specifically Deuterated Essential Lipids as New Drugs Against Neuronal, Retinal and Vascular Degeneration,” Drug Discovery Today 25, no. 8 (2020): 1469–1476.

[85] R. D. Jansen-van Vuuren, L. Jedlovčnik, J. Košmrlj, T. E. Massey, and V. Derdau, “Deuterated Drugs and Biomarkers in the COVID-19 Pandemic,” ACS Omega 7, no. 46 (2022): 41840–41858.

[86] A. Hatami, C. Zhu, A. Relaño-Gines, et al., “Deuterium-reinforced Linoleic Acid Lowers Lipid Peroxidation and Mitigates Cognitive Impairment in the Q140 Knock in Mouse Model of Huntington's Disease,” Febs Journal 285, no. 16 (2018): 3002–3012.

[87] E. A. Turovsky, E. G. Varlamova, S. V. Gudkov, and E. Y. Plotnikov, “The Protective Mechanism of Deuterated Linoleic Acid Involves the Activation of the Ca2+ Signaling System of Astrocytes in Ischemia in Vitro,” International Journal of Molecular Sciences 22, no. 24 (2021): 13216.

[88] J. F. P. Berbée, I. M. Mol, G. L. Milne, et al., “Deuterium-reinforced Polyunsaturated Fatty Acids Protect Against Atherosclerosis by Lowering Lipid Peroxidation and Hypercholesterolemia,” Atherosclerosis 264 (2017): 100–107.

[89] M. Rosell, M. Giera, P. Brabet, et al., “Bis-allylic Deuterated DHA Alleviates Oxidative Stress in Retinal Epithelial Cells,” Antioxidants 8, no. 10 (2019): 447.

[90] J. Wan, Y. Guo, H. Chen, et al., “Application and Development of Deuterium Metabolic Imaging in Tumor Glucose Metabolism: Visualization of Different Metabolic Pathways,” Frontiers in Oncology 13 (2023): 1285209.

[91] R. B. Kargbo, “Psilocybin Therapeutic Research: The Present and Future Paradigm,” Acs Medicinal Chemistry Letters 11, no. 4 (2020): 399–402.

[92] R. B. Kargbo, “Application of Deuterated N,N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders,” Acs Medicinal Chemistry Letters 13, no. 9 (2022): 1402–1404.

[93] N. A. Meanwell, The Influence of Bioisosteres in Drug Design: Tactical Applications to Address Developability Problems (2013), 283–381.

[94] L. I. H. Joyce, S. Wen, C. Cheng, X. Chen, and G. Shang, “Deuterated compounds for treating fabry, gaucher, parkinson's and related diseases and conditions, and compositions and methods thereof,” Published online 2019:US20190248790A1.

[95] X. M. Wang, J. Wang, and V. Fokina, “Effect of Deuteration on the Single Dose Pharmacokinetic Properties and Postoperative Analgesic Activity of Methadone,” Drug Metabolism and Pharmacokinetics 47 (2022): 100477.

[96] S. Seneff and A. M. Kyriakopoulos, “Deuterium Trafficking, Mitochondrial Dysfunction, Copper Homeostasis, and Neurodegenerative Disease,” Frontiers in Molecular Biosciences 12 (2025): 1639327.

[97] N. B. Pestov, I. A. Okkelman, V. V. Shmanai, A. L. Hurski, A. J. Giaccia, and M. S. Shchepinov, “Control of Lysyl Oxidase Activity Through Site-specific Deuteration of Lysine,” Bioorganic & Medicinal Chemistry Letters 21, no. 1 (2011): 255–258.

[98] C. B. Woodcock, E. A. Ulashchik, N. E. Poopeiko, V. V. Shmanai, N. O. Reich, and M. S. Shchepinov, “Rational Manipulation of DNA Methylation by Using Isotopically Reinforced Cytosine,” Chembiochem 17, no. 21 (2016): 2018–2021.

[99] M. Kulis and M. Esteller, DNA Methylation and Cancer (2010), 27–56.

[100] C. Filì, A. Candoni, M. E. Zannier, et al., “Efficacy and Toxicity of Decitabine in Patients With Acute Myeloid Leukemia (AML): A Multicenter Real-world Experience,” Leukemia Research 76 (2019): 33–38.

[101] Z. P. Vang, A. Reyes, R. E. Sonstrom, et al., “Copper-Catalyzed Transfer Hydrodeuteration of Aryl Alkenes With Quantitative Isotopomer Purity Analysis by Molecular Rotational Resonance Spectroscopy,” Journal of the American Chemical Society 143, no. 20 (2021): 7707–7718.

[102] Y. Cherrah, J. B. Falconnet, M. Desage, J. L. Brazier, R. Zini, and J. P. Tillement, “Study of Deuterium Isotope Effects on Protein Binding by Gas Chromatography/Mass Spectrometry. Caffeine and Deuterated Isotopomers,” Biological Mass Spectrometry 14, no. 11 (1987): 653–657.

[103] D. P. Richards, L. E. Sojo, and B. O. Keller, “Quantitative Analysis With Modern Bioanalytical Mass Spectrometry and Stable Isotope Labeling,” Journal of Labelled Compounds and Radiopharmaceuticals 50, no. 11-12 (2007): 1124–1136.

[104] Y. Yamazaki, S. I. Ogawa, and K. Shibuya, “Synthesis of Highly Deuterium-labeled (R)-K-13675, PPAR α Agonist, for Use as an Internal Standard for Low-level Quantification of Drugs in Plasma,” Bioorganic & Medicinal Chemistry 17, no. 5 (2009): 1911–1917.

[105] R. B. Murphy, N. A. Wyatt, B. H. Fraser, et al., “A Rapid MS/MS Method to Assess the Deuterium Kinetic Isotope Effect and Associated Improvement in the Metabolic Stability of Deuterated Biological and Pharmacological Molecules as Applied to an Imaging Agent,” Analytica Chimica Acta 1064 (2019): 65–70.

[106] J. Wang, W. Zhang, T. Huang, P. Su, and Y. Yang, “Quantification of a Volatile Deuterated Compound by the Differential Scanning Calorimetry Combined With Quantitative Nuclear Magnetic Resonance and Its Verification by the Mass Balance Method Combined With Gas Chromatography-mass Spectrometry,” Talanta 246 (2022): 123538.

[107] A. S. Marriott, A. M. Boyd, E. Quirk, and J. Chadwick, “A Chemometric Model for the Quantitative Determination of Isotopic Impurities in D-methylamine Hydrochloride by Fourier-transform Infrared Spectroscopy,” Journal of Pharmaceutical and Biomedical Analysis 205 (2021): 114337.

[108] A. K. Cho, B. Lindeke, B. J. Hodshon, and D. J. Jenden, “Deuterium Substituted Amphetamine as an Internal Standard in a Gas Chromatographic/Mass Spectrometric (GC/MS) Assay for Amphetamine,” Analytical Chemistry 45, no. 3 (1973): 570–574.

[109] P. Grocholska and R. Bąchor, “Trends in the Hydrogen−Deuterium Exchange at the Carbon Centers. Preparation of Internal Standards for Quantitative Analysis by LC-MS,” Molecules 26, no. 10 (2021): 2989.

[110] G. K. Szabo, R. J. Pylilo, R. J. Perchalski, and T. R. Browne, “Simultaneous Separation and Determination (in serum) of Phenytoin and Carbamazepine and Their Deuterated Analogues by High-performance Liquid Chromatography—ultraviolet Detection for Tracer Studies,” Journal of Chromatography A 535 (1990): 271–277.

[111] R. R. Greenberg, P. Bode, and E. A. De Nadai Fernandes, “Neutron Activation Analysis: A Primary Method of Measurement,” Spectrochim Acta Part B At Spectrosc 66, no. 3-4 (2011): 193–241.

[112] P. Lesot, “Determination of the Natural Deuterium Distribution of Fatty Acids by Application of 2H 2D-NMR in Liquid Crystals: Fundamentals, Advances, Around and Beyond,” Liquid Crystals 47, no. 13 (2020): 1886–1910.

[113] P. W. Manley, F. Blasco, J. Mestan, and R. Aichholz, “The Kinetic Deuterium Isotope Effect as Applied to Metabolic Deactivation of imatinib to the Des-methyl Metabolite, CGP74588,” Bioorganic & Medicinal Chemistry 21, no. 11 (2013): 3231–3239.

[114] A. V. Syroeshkin, T. V. Pleteneva, and E. V. Uspenskaya, “Deuterium as a Tool for Changing the Properties of Pharmaceutical Substances (REVIEW),” International Journal of Applied Pharmaceutics 13, no. 4 (2021): 65–73.

[115] J. T. Weatherford-Pratt, J. A. Smith, M. S. Holdren, et al., “Optimizing the Synthesis of Deuterated Isotopomers and Isotopologues of Cyclohexene Using Molecular Rotational Resonance Spectroscopy,” Journal of the American Chemical Society 147, no. 38 (2025): 35055–35068.

[116] N. A. Meanwell, “Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design,” Journal of Medicinal Chemistry 61, no. 14 (2018): 5822–5880.

[117] Y. Pan, “The Dark Side of Fluorine,” Acs Medicinal Chemistry Letters 10, no. 7 (2019): 1016–1019.

[118] J. Helfenbein, C. Lartigue, E. Noirault, et al., “Isotopic Effect Study of Propofol Deuteration on the Metabolism, Activity, and Toxicity of the Anesthetic,” Journal of Medicinal Chemistry 45, no. 26 (2002): 5806–5808.

[119] W. Li, J. Rabeah, F. Bourriquen, et al., “Scalable and Selective Deuteration of (hetero)Arenes,” Nature Chemistry 14, no. 3 (2022): 334–341.

[120] B. Czeskis, C. S. Elmore, A. Haight, et al., “Deuterated Active Pharmaceutical Ingredients: A Science-based Proposal for Synthesis, Analysis, and Control. Part 1: Framing the Problem,” Journal of Labelled Compounds and Radiopharmaceuticals 62, no. 11 (2019): 690–694.

[121] M. Serafini, S. Cargnin, A. Massarotti, G. C. Tron, T. Pirali, and A. A. Genazzani, “What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends Using INN Publications,” Journal of Medicinal Chemistry 64, no. 8 (2021): 4410–4429.

[122] A. V. Karkhanis, G. Venkatesan, R. Kambayashi, et al., “Site-directed Deuteration of Dronedarone Preserves Cytochrome P4502J2 Activity and Mitigates Its Cardiac Adverse Effects in Canine Arrhythmic Hearts,” Acta Pharmaceutica Sinica B 12, no. 10 (2022): 3905–3923.

[123] S. Frank, C. M. Testa, D. Stamler, et al., “Effect of Deutetrabenazine on Chorea among Patients with Huntington Disease,” Jama 316, no. 1 (2016): 40.

[124] C. Beaudoin-Chabot, L. Wang, A. V. Smarun, D. Vidović, M. S. Shchepinov, and G. Thibault, “Deuterated Polyunsaturated Fatty Acids Reduce Oxidative Stress and Extend the Lifespan of C. elegans,” Frontiers in Physiology 10 (2019): 641.

[125] C. Schmidt, “First Deuterated Drug Approved,” Nature Biotechnology 35, no. 6 (2017): 493–494.

[126] S. L. Harbeson, A. J. Morgan, J. F. Liu, et al., “Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor With Differentiated Pharmacokinetics for Clinical Development,” Journal of Pharmacology and Experimental Therapeutics 362, no. 2 (2017): 359–367.

[127] B. King, N. Mesinkovska, P. Mirmirani, et al., “Phase 2 Randomized, Dose-ranging Trial of CTP-543, a Selective Janus Kinase Inhibitor, in Moderate-to-severe Alopecia Areata,” Journal of the American Academy of Dermatology 87, no. 2 (2022): 306–313.

[128] K. R. Karst, “FDA Determines That Deuterated Compounds Are NCEs and Different Orphan Drugs versus Non-deuterated Versions,” FDA Law Blog (2017).

[129] S. Cargnin, M. Serafini, and T. Pirali, “A Primer of Deuterium in Drug Design,” Future Medicinal Chemistry 11, no. 16 (2019): 2039–2042.

[130] R. D. Tung, “Deuterium Medicinal Chemistry Comes of Age,” Future Medicinal Chemistry 8, no. 5 (2016): 491–494.

[131] S. Yang and S. Kar, “Application of Artificial Intelligence and Machine Learning in Early Detection of Adverse Drug Reactions (ADRs) and Drug-induced Toxicity,” Artificial Intelligence Chemistry 1, no. 2 (2023): 100011.

[132] R. Creer, “Regulatory Considerations for Deuterated Products,” Salamandra (2025).

[133] D. Knutson, E. Coddens, and O. Winsor, “Deuteration in API Development: Synthetic, Analytical and Engineering Considerations,” Sterling Pharma Solutions Limited (2026).

[134] G. S. Timmins, “Deuterated Drugs; Updates and Obviousness Analysis,” Expert Opinion on Therapeutic Patents 27, no. 12 (2017): 1353–1361.

[135] M. Dean and V. Sung, “Review of deutetrabenazine: A Novel Treatment for Chorea Associated With Huntington's Disease,” Drug Design, Development and Therapy 12 (2018): 313–319.

[136] S. E. Sloane, Z. P. Vang, G. Nelson, et al., “Precision Deuteration Using Cu-Catalyzed Transfer Hydrodeuteration to Access Small Molecules Deuterated at the Benzylic Position,” JACS Au 3, no. 6 (2023): 1583–1589.

[137] F. Bu, Y. Deng, P. Shi, et al., “Thiol-Regulated Rhodium Nanocatalyst for Electrochemical Reductive Perdeuteration of Alkenes,” Journal of the American Chemical Society 148, no. 7 (2026): 7322–7332.

[138] W. J. Kerr, G. J. Knox, and L. C. Paterson, “Recent Advances in Iridium(I) Catalysis towards Directed Hydrogen Isotope Exchange,” Journal of Labelled Compounds and Radiopharmaceuticals 63, no. 6 (2020): 281–295.

[139] L. Neubert, D. Michalik, S. Bähn, et al., “Ruthenium-Catalyzed Selective α,β-Deuteration of Bioactive Amines,” Journal of the American Chemical Society 134, no. 29 (2012): 12239–12244.

[140] Z. Guo, O. Smutok, G. R. Lee, et al., “Artificial Allosteric Protein Switches With Machine-learning-designed Receptors,” Nature Biotechnology (2026). Epub ahead of print.

[141] R. Advincula, I. Ivanov, R. Vasudevan, et al., “Harnessing Data and Control With AI/ML-driven Polymerization and Copolymerization,” Faraday Discussions 262 (2026): 478–499.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.